Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.
- DOI
- 10.21037/jtd-23-686
- Published
- 2023 Nov 30
- Container
- Journal of thoracic disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.21037/jtd-23-686,
title = {Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.},
author = {Gilardone S and Thapa R and Laborde J and Shafique M and Saltos A and Creelan B and Tanvetyanon T and Chiappori A and Simon G and Haura EB and Gray JE and Chen DT and Melzer D and Pellini B},
year = {2023},
journal = {Journal of thoracic disease},
doi = {10.21037/jtd-23-686},
url = {https://doi.org/10.21037/jtd-23-686}
}RIS
TY - JOUR TI - Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. AU - Gilardone S AU - Thapa R AU - Laborde J AU - Shafique M AU - Saltos A AU - Creelan B AU - Tanvetyanon T AU - Chiappori A AU - Simon G AU - Haura EB AU - Gray JE AU - Chen DT AU - Melzer D AU - Pellini B PY - 2023 JO - Journal of thoracic disease DO - 10.21037/jtd-23-686 UR - https://doi.org/10.21037/jtd-23-686 ER -
APA
S, G., R, T., J, L., M, S., A, S., B, C., T, T., A, C., G, S., EB, H., JE, G., DT, C., D, M., & B, P. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.. Journal of thoracic disease. https://doi.org/10.21037/jtd-23-686
Source records
- pubmed · retrieved 2026-09-26T00:10:50.460Z